Search clinical trials for: Hemagglutinins

Total 26 results

Protein Sciences Corporation

Completed

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Influenza

United States
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Completed

Recombinant H7 Hemagglutinin Influenza Vaccine Trial (FLU007)

Influenza, Avian

Australia
VaxInnate Corporation

Unknown

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

Influenza

United States
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Influenza

United States
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute; Flinders University

Completed

A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (FLU003)

Influenza

Australia
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults (PSC25)

Influenza

United States
Protein Sciences Corporation

Completed

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza

United States
Sanofi
Protein Sciences Corporation

Completed

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok

Influenza

United States
VaxInnate Corporation

Unknown

Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years

Influenza

Australia
VaxInnate Corporation
Department of Health and Human Services; Accelovance

Unknown

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Influenza

United States
Protein Sciences Corporation

Completed

Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV

Influenza

United States
Laboratorios Liomont
EPIC Research CRO; ILS Clinical Research; Q Square Solutions

Completed

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Influenza, Human

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
University Hospital, Geneva

Recruiting

Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines (Pertagen2x)

Pertussis | Vaccine-Preventable Diseases

Switzerland
Vanderbilt University Medical Center

Completed

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Flu Vaccine

United States
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Hong Kong
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
The University of Hong Kong
Centers for Disease Control and Prevention

Active, not recruiting

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong (PIVOT)

Influenza, Human

China
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Healthy Volunteers | Influenza Immunization

France, Belgium, Germany, Italy, Netherlands, Poland
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 (CONTENT1)

Overactive Bladder | Urinary Incontinence

United States, Korea, Republic of, Czechia, Netherlands, Romania, Poland, Turkey, Portugal, Canada, Italy
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine
University Hospitals Cleveland Medical Center

Terminated

Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer

Scar

United States
Ipsen

Completed

Dysport in Hallux Abducto Valgus (HAV) Phase IIa (DYSTANCE)

Hallux Abducto Valgus

United States

3

Subscribe